SHORT MINI-FUTURE - BIOGEN IDEC | Delayed Deutsche Boerse AG 09:31:46 21/05/2024 BST | ||
| 20.36 EUR | -0.29% |
|
| Current month | -7.81% | ||
| 1 month | -16.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 21/05/24 | 20.36 | -0.29% |
| 20/05/24 | 20.42 | -0.73% |
| 17/05/24 | 20.57 | -0.10% |
| 16/05/24 | 20.59 | +3.21% |
| 15/05/24 | 19.95 | -5.32% |
Delayed Quote Deutsche Boerse AG
Last update May 21, 2024 at 09:31 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VQ8H9L |
| ISIN | DE000VQ8H9L9 |
| Date issued | 09/06/2021 |
| Strike | 452.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.91 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.87 € |
|---|---|
| Lowest since issue | 2.97 € |
| Spread | 0.16 € |
| Spread % | 0.78% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
231.6
USD
Average target price
285.9
USD
Spread / Average Target
+23.47%
- Stock Market
- Certificates
- Certificat
